Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSC Construct for Osteonecrosis of the Jaw
NCT02566681Phase 1Unknown
- Sponsor
- Red de Terapia Celular
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow stem cells in osteonecrosis of the jaw (ONJ), sponsored by Red de Terapia Celular. Primary endpoints: Rate of serious adverse events related to the procedure at 24 months and Rate of non-serious adverse events related to the procedure at 24 months. Status: unknown.
02
Drugs
autologous bone marrow stem cells
03
Conditions
osteonecrosis of the jaw (ONJ)
Beyond the preview
Go deeper on NCT02566681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566681.